期刊文献+

不同干扰素与利巴韦林联用治疗慢性丙型肝炎的疗效评价 被引量:1

收藏 分享 导出
摘要 目的:评价不同种类干扰素与利巴韦林联用治疗慢性丙型肝炎(CHC)的疗效,为CHC患者抗病毒治疗方案的选择提供依据。方法:将96例CHC初治患者随机分成治疗组(50例)和对照组(46例);治疗组患者予聚乙二醇干扰素α-2b,对照组患者(46例)予国产重组人干扰素α-2b,两组患者均予利巴韦林联用治疗;疗程结束后随访24周,评价两组患者病毒学应答情况。结果:经治疗和测试,治疗组基因Ⅰ型患者为32例,其快速病毒学应答率(RVR)、早期病毒学应答率(EVR)、治疗终点病毒学应答率(ETVR)和持续病毒学应答率(SVR)显著高于对照组(29例),两组资料经比较其差异有统计学意义(P〈0.05);治疗组非基因Ⅰ型患者为18例,其RVR、EVR、ETVR和SVR略高于对照组(17例),经比较其差异无统计学意义(P〉0.05)。结论:对于基因Ⅰ型CHC患者,治疗组患者经治疗后,其SVR显著优于对照组,而对于非基因Ⅰ型CHC患者予国产重组人干扰素α-2b与利巴韦林联用治疗,更符合我国国情。
作者 李国勇
出处 《抗感染药学》 2014年第5期528-530,共3页 Anti-infection Pharmacy
作者简介 李国勇(1968-),男;副主任医师 [联系方式]:13328007898 E-mail:liguoyong0727@163.com
  • 相关文献

参考文献6

  • 1Omata M, Kanda T, Yu ML, et al, APASL consensus state- ments and management algorithms for hepatitis C virus infecfion[J].Hepatol Intern, 2012, 6: 409-435. 被引量:1
  • 2Hezode C, Castera L, Roudot-Thoraval F, et al. Liver stiff- ness diminishes with antiviral response in chronic heptitis C[J].4liment Pharmcol Ther, 2011, 34(6) : 656-663. 被引量:1
  • 3European Association for the Study of the Liver. EASL clinical practice guidelines: management and treatment of hepatitis C virus infection[J].J Hepatol, 2011, 55(2):245- 264. 被引量:1
  • 4中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华肝脏病杂志,2004;12:194-198. 被引量:17
  • 5王豪.聚乙二醇干扰素治疗丙型肝炎[J].中华消化杂志,2004,24(1):47-49. 被引量:4
  • 6Ge DL, Fellay J, Thompson A J, et al. Genetic variation in IL 28B predicts hepatitis C treatment-induced viralclear- ance[J]Nature, 2009, 461 : 399-401. 被引量:1

二级参考文献5

  • 1Poynard T,Leroy V,Cohard M,et al.Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration[].Hepatology.1996 被引量:1
  • 2Reichard O,Andersson J,Schvarcz R,et al.Ribavirin treatment for chronic hepatitis C[].The Lancet.1991 被引量:1
  • 3Wills RJ.Clinical pharmacokinetics of interferons[].Clinical Pharmacokinetics.1990 被引量:1
  • 4Reddy RK,Layden T,Poulakos J.Daily or twice daily interferon alfacon-1 (INFERGEN) administration achieves potimal viral suppression compared to thrice weekly dosing schedules in subjects with genotype 1 chronic hepatitis C virus (HCV) infection[].Hepatology.1999 被引量:1
  • 5Schalm SW,Weiand O,Hansen BE,et al.Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patients data of six controlled trials[].Gastroenterology.1999 被引量:1

共引文献19

同被引文献22

  • 1Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61(1 Suppl): S45-S57. 被引量:1
  • 2Nettels RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virusgenotype 1 [J]. Hepatology, 2011, 54(6): 1956-1965. 被引量:1
  • 3Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trails: is blinding necessary? [J]. Control Clin Trials, 1996, 17(1): 1-12. 被引量:1
  • 4Hezode C, Hirschfield GM, Ghesquiere Wj et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study[J]. Gut, 2015, 64(6): 948-956. 被引量:1
  • 5Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection[J]. Gastroenterology, 2015, 148(2): 355-366. 被引量:1
  • 6Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasivir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection[J]. Antivir Ther, 2014, 19(5): 491-499. 被引量:1
  • 7Izumi N, Yokosuka O, Kawada N, et al. Daclatasivir combined with peginterferon alfa-2b and ribavirin in Japanese patient infected with hepatitis C genotype 1 [J]. Antivir Ther, 2014, 19(5): 501-510. 被引量:1
  • 8Pol S, Ghali RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial[J]. Lancet Infect Dis, 2012, 12(9): 671-677. 被引量:1
  • 9Katziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa/2a and ribaviron in HCV-infected prior null and partial responders: 12 week results of phase 2b command-2 trial[J]. J Hepatol, 2012, S6(Suppl 2): 478-479. 被引量:1
  • 10European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection[J]. J Hepatol, 2014, 60(1): 392-420. 被引量:1

引证文献1

二级引证文献5

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈